ESMO: Community Oncology: Ensuring the Best Standards of Care

“The important thing is that community oncologists should not work alone. They should be part of a network and participate in a common reflection and also work with others in clinical research. In France, community oncologists work closely with university hospitals or big cancer centers and are in contact with larger teams. National and international guidelines are followed and ensure that patients receive quality treatment.”

abstract: Pleural Effusion Detected at CT prior to Primary Cytoreduction for Stage III or IV Ovarian Carcinoma: Effect on Survival

Purpose: To determine the prognostic importance of pleural effusions on preoperative computed tomographic (CT) images in patients with advanced epithelial ovarian cancer.

abstract : Red and processed meat consumption and risk of ovarian cancer: a dose-response meta-analysis of prospective studies : British Journal of Cancer

Conclusion:

Results from this dose-response meta-analysis suggest that red and processed meat consumption is not associated with risk of ovarian cancer. Although a lower consumption of red and processed meat may offer protection against other types of cancer, other interventions are needed to reduce the risk of ovarian cancer.

David Moher - Systematic Reviews & Prospero Register | Open Medicine Blog-PROSPERO International

PROSPERO - International prospective register of systematic reviews

PROSPERO is an international database of prospectively registered systematic reviews in health and social care. Key features from the review protocol are recorded and maintained as a permanent record in PROSPERO. This will provide a comprehensive listing of systematic reviews registered at inception, and enable comparison of reported review findings with what was planned in the protocol.

Substantial changes to the review questions or methods

• It can be difficult to decide whether an update to a review is in fact a new review. There is little published guidance on this. PROSPERO adopts a pragmatic approach. If changes to the review questions or methods are so substantial that they require major changes to the original protocol, this should be regarded as a new review rather than an update.

Examples that would constitute a new review

• addition of new treatment comparisons
  e.g. direct comparison of different drugs, when the old review included only comparisons of drug with placebo
• substantial changes to the population being studied
  e.g. adding adults to a review that was previously restricted to children
• exclusion criteria in the old review become inclusion criteria in the new review
• introduction of new analysis techniques
  e.g. a switch from aggregate data meta-analyses to individual participant meta-analyses.
  

If in doubt, a new record for a new review should be created. This will minimise the complexity of the editing to the original record in PROSPERO and make it easier for users to distinguish between the original review and the later version. Links between the new and original review can be added in the registration form.

Mechanical Bowel Preparation for Gynecologic Laparoscopy: A Prospective Randomized Trial of Oral Sodium Phosphate Solution vs Single Sodium Phosphate Enema (including safety issues)

Mechanical Bowel Preparation for Gynecologic Laparoscopy: A Prospective Randomized Trial of Oral Sodium Phosphate Solution vs Single Sodium Phosphate Enema

References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Study Objective

To compare the effect of mechanical bowel preparation using oral sodium phosphate (NaP) solution vs single NaP enema on the quality of the surgical field in patients undergoing advanced gynecologic laparoscopic procedures.

The Art of Oncology series (ASCO) full free access: Negotiations and Love Songs

full free access: (2010) MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer

Background

Approximately 10% of Lynch syndrome families have a mutation in MSH6 and fewer families have a mutation in PMS2. It is assumed that the cancer incidence is the same in families with mutations in MSH6 as in families with mutations in MLH1/MSH2 but that the disease tends to occur later in life, little is known about families with PMS2 mutations. This study reports on our findings on mutation type, cancer risk and age of diagnosis in MSH6 and PMS2 families..........cont'd

"Lynch syndrome is an autosomal dominantly inherited cancer syndrome characterised by early onset epithelial cancers. Patients with Lynch syndrome have an increased risk of developing malignancies during their lifetime, at a mean age of disease onset that is significantly lower than that observed in the general population. In addition to the high risk of developing CRC, Lynch syndrome patients are also at risk of developing malignancies in a variety of organs that include the uterus, small bowel, stomach, ovary, bladder, pancreas and the urinary tract [2,3]."